EDSA.US Edesa Biotech Inc

Healthcare Biotechnology USA Stocks
1.94 USD
Close of Nov 14, 2026
0.7200 20.32
Market cap
USD 26.2M
P/E
-
P/B
50.50x
ROE
-179.7%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Jun 2026.

Is EDSA.US undervalued?

Graham number

The Graham number of Edesa Biotech Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Edesa Biotech Inc fundamental analysis

No fundamental analysis for Edesa Biotech Inc yet.

Edesa Biotech Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Edesa Biotech Inc

Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. It develops EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that has completed Phase 3 clinical study t…

Full company profile